Posttransplant Allosensitization in Low Immunological Risk Kidney and Kidney-Pancreas Graft Recipients
Figure 2
Graft survival censored for death with a functioning graft according to presence of anti-HLA antibodies against class I, class II, or class I/II at 6 months after transplant. Patients with antibody positivity for class II () (83.3%, log-rank test ) or class I/II () (70%, log-rank test ) showed a significantly lower survival rate at 5 years than antibody-negative patients (). Graft survival was similar in antibody-negative patients and those positive only for class I () anti-HLA antibodies (96.4% versus 98% resp., log-rank test ).
